Thermo Fisher Scientific AF9 Polyclonal Antibody

Applications

Tested Dilution

Publications

Western Blot (WB)

1:500-1:3,000

-

Immunohistochemistry (Paraffin) (IHC (P))

1:100-1:1,000

-

Immunocytochemistry (ICC/IF)

1:100-1:1,000

-

ChIP assay (ChIP)

Assay-dependent

-

ChIP-sequencing (ChIP-Seq)

Assay-dependent

-

Product Specifications

Species Reactivity

Human

Host/Isotype

Rabbit / IgG

Class

Polyclonal

Type

Antibody

Immunogen

Recombinant fragment corresponding to a region within amino acids 281 and 532 of Human AF9 if (typeof window.$mangular === undefined || !window.$mangular) { window.$mangular = {}; } $mangular.antigenJson = \[{targetFamily:AF9,uniProtId:P42568-1,ncbiNodeId:9606,antigenRange:281-532,antigenLength:568,antigenImageFileName:PA5-27797_AF9_P42568-1_Rabbit.svg,antigenImageFileNamePDP:PA5-27797_AF9_P42568-1_Rabbit_PDP.jpeg,sortOrder:1}\]; $mangular.isB2BCMGT = false; $mangular.isEpitopesModalImageMultiSizeEnabled = true;

View immunogen .st0{fill:#FFFFFF;} .st1{fill:#1E8AE7;}

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Concentration

0.46 mg/mL

Purification

Antigen affinity chromatography

Storage buffer

PBS, pH 7, with 20% glycerol, 1% BSA

Contains

0.025% ProClin 300

Storage conditions

Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.

Shipping conditions

Wet ice

RRID

AB_2545273

Product Specific Information

Recommended positive controls: 293T, A431, HeLa, HepG2, THP-1, MLLT3 shRNA-transfected 293T, SEM-K2.

Predicted reactivity: Mouse (98%), Rat (98%), Bovine (97%).

Store product as a concentrated solution. Centrifuge briefly prior to opening the vial.

Target Information

The human AF9 gene is one of the most common fusion partner genes with the ALL1 gene at 11q23 (also called MLL), resulting in the t(9;11)(p22;q23). The AF9 gene is more than 100 kb, and 2 patient breakpoint cluster regions (BCRs) have been identified; BCR1 is within intron 4, previously called site A, whereas BCR2 or site B spans introns 7 and 8. Several different structural elements have been identified in AF9, including a colocalizing in vivo DNA topo II cleavage site and an in vitro DNase I hypersensitive (DNase 1 HS) site in intron 7 in BCR2. Reversibility experiments demonstrated a religation of the topo II cleavage sites. In addition, 2 scaffold associated regions (SARs) are located centromeric to the topo II and DNase I HS cleavage sites and border breakpoint regions in 2 leukemic cells lines: SAR1 is located in intron 4, whereas SAR2 encompasses parts of exons 5-7. The patient breakpoint regions of AF9 share the same structural elements as the MLL BCR. A DNA breakage and repair model for nonhomologous recombination between MLL and its partner genes, particularly AF9, has been proposed.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.